1501TiPAfatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study). (23rd October 2018) - Hata, A; Katakami, N; Nishino, K; Mori, M; Yokoyama, T; Kurata, T; Tachihara, M; Takase, N; Daga, H; Kijima, T; Morita, S; Sakai, K; et al.